Background
==========

The concept of health-related quality of life (HRQoL) in patients with chronic kidney disease (CKD), including end-stage renal disease (ESRD), has evolved since the inception of renal replacement therapy, evolving from ensuring easy survival to achieving a sense of well-being \[[@B1]\]. Patients with CKD tend to show a reduction in their quality of life (QoL) because of the restrictions resulting from CKD treatment. Multiple factors, such as the presence of co-morbidities, can further reduce the QoL. Interventions aiming to improve the clinical condition and the QoL of these patients are of paramount importance, since the latter is directly associated with mortality. The association between the reduction of QoL and preventable and controllable factors including diabetes \[[@B2]\], old age \[[@B3]\], inadequacy of dialysis, inflammation and poor nutrition, is still unclear. In addition, studies have shown that dialysis initiation improves the QoL in ESRD patients \[[@B4]-[@B8]\]. However, the association between dialysis adequacy indices or nutritional parameters and QoL is inconsistent. These results may be inconsistent owing to the small sample of patients in those studies, non-ESRD-specific assessments, inadequate observation periods, or other factors.

Several validated, disease-specific HRQoL questionnaires can be used for the dialysis cohort, such as the World Health Organization Quality of Life Survey (WHOQOL), Short Form (SF)-36 health survey, the Kidney Disease Quality of Life (kDQOL), and the Choices Health Experiences Questionnaire (CHEQ). Patients with Kt/V urea values above 2.0 undergoing peritoneal dialysis (PD) were found to have higher total SF-36 scores than patients with Kt/V urea values below 2.0 \[[@B6]\], although some researchers argue that the correlation between Kt/V urea values and SF-36 scores is not significant \[[@B8]\]. There are only 2 validated native-language editions of questionnaires in Taiwan: the WHOQOL and the SF-36. In Taiwan, the SF-36 questionnaires have been used as a validation tool in a multi-center study comparing the QoL between PD and hemodialysis patients \[[@B9]\].

In this study, we used the SF-36 to assess the QoL in an incident cohort of PD patients. The purpose of the study was to investigate which components of the SF-36 could be improved after PD initiation. In addition, the influences of PD adequacy indices and nutritional status measures on the components of the SF-36 were explored.

Methods
=======

Incident ESRD patients who consulted a PD institution at a medical center in southern Taiwan between January 2009 and June 2010 were enrolled in this prospective study. The following were the inclusion criteria: (1) new PD patients; (2) aged above 17 years; (3) able to express themselves; (4) no history of psychiatric disease; and (5) clinically stable with no evidence of chronic or acute infections, inflammatory disorders, malignancy, or anti-inflammatory drug use 3 months prior to enrollment. The exclusion criteria were as follows: (1) aged below 17 years; (2) unable to receive PD therapy for three months after PD initiation; (3) unable to complete the questionnaires by themselves; (4) major clinical events requiring hospital admission; and (5) discontinuation of PD owing to kidney transplantation, technique failure, death, transfer to hemodialysis, or loss to follow-up. As per the study protocol requirement, all patients had completed at least 6 months of consecutive PD therapy, and 77 of 80 clinically stable patients (38 men and 39 women) were finally eligible. The mean age was 47.3 years. All the patients were dialyzed using commercially available dialysate (pH 5.2; Dianeal PD solution; Baxter, Singapore) containing 40 mmol/L lactate. Forty-five patients received continuous ambulatory PD (CAPD) therapy, with 4 exchanges every day. Thirty-two patients received automated PD (APD) therapy.

The QoL was measured using the Chinese version of the Short Form (SF)-36 health survey questionnaire (Taiwan Standard Version 1.0)---a generic self-report QoL instrument---comprising 36 items, which are assigned to the following 8 domains: general health, physical functioning, role limitation due to physical problems, bodily pain, mental health, social functioning, role limitation due to emotional problems, and vitality. The first 4 domains constitute the physical component scale, and the next 4 constitute the mental component scale. Higher scores indicate better QoL.

All the patients were asked to complete the SF-36 questionnaire prior to PD therapy as well as 6 months after PD initiation. A standard peritoneal equilibrium test (PET) was performed in the first month and then after 6 months after PD initiation. The clinical characteristics of all patients, including demographic and biochemical data, PD adequacy indices of renal and peritoneal Kt/V urea and creatinine clearance (Ccr), and nutritional indices (serum albumin, normalized protein catabolic rate \[nPCR\]) were collected as baseline information at the beginning of the study. These data were collected again at 6 months for statistical analysis.

The protocol for the study was approved by the Committee on Human Research at Kaohsiung Chang Gung Memorial Hospital (CMRPG880091) and conducted in accordance with the Declaration of Helsinki. All participants signed an informed consent form before taking part in the study.

Statistical analysis
--------------------

Using a general linear model, we determined an applicable Kt/V value to determine the effect of Kt/V on the QoL (Table [1](#T1){ref-type="table"}). On the basis of the Kt/V value selected by us, the following patient characteristics were recorded, grouped, and compared using the Mann--Whitney test, Chi-square test, or likelihood ratio test: age; gender; clinical data including values for peritoneal urea Kt/V, residual renal urea Kt/V, total Kt/V, weekly peritoneal Ccr, weekly residual renal Ccr, total weekly Ccr, high-sensitivity C-reactive protein (hs-CRP), albumin, GPT, hemoglobin (Hb), and nPCR; and the 8 multi-item domains of the SF-36. Thus, age, peritoneal Kt/V, residual renal WCcr, and nPCR were regarded as independent variables for exploring the effect of PD therapy on SF-36 scores. Statistical analyses were performed using the IBM SPSS Statistics 19 (SPSS Inc. Chicago, IL) program.

###### 

The influence of stratified peritoneal Kt/V urea levels on SF-36 domains

  **SF-36 Domains**      **Physical functioning**   **Role limitation - physical**   **Bodily pain**   **General health**   **Vitality**   **Social functioning**   **Role limitation - emotional**   **Mental health**                                                            
  ---------------------- -------------------------- -------------------------------- ----------------- -------------------- -------------- ------------------------ --------------------------------- ------------------- ------- ------- -------- ------- ------- ------- ------- -------
  Peritoneal Kt/V urea                                                                                                                                                                                                                                                              
  \<1.2                  18.4                       0.074                            13.59             0.224                21.4           0.078                    31.75                             0.039               4.51    0.407   -3.65    0.814   3.51    0.754   4.97    0.440
  1.2≦Kt/V\<1.3          27.62                      0.015                            27.27             0.027                5.46           0.676                    37.49                             0.025               8.10    0.174   6.47     0.702   14.95   0.224   11.18   0.113
  1.3≦Kt/V\<1.4          24.92                      0.016                            27.39             0.016                22.7           0.061                    37.47                             0.015               5.94    0.274   7.84     0.612   17.80   0.115   7.64    0.235
  1.4≦Kt/V\<1.5          20.71                      0.047                            24.73             0.030                25.04          0.042                    27.91                             0.070               9.94    0.073   11.77    0.452   10.81   0.341   10.64   0.104
  1.5≦Kt/V\<1.6          4.98                       0.678                            14.64             0.266                25.51          0.075                    12.28                             0.491               -1.53   0.811   -14.57   0.426   0.70    0.957   4.14    0.585
  ≧1.6                   20.91                      0.028                            18.96             0.067                19.83          0.076                    43.74                             0.002               10.59   0.037   6.66     0.641   12.33   0.235   7.55    0.204

Statistical method: general linear model.

Results
=======

Association between the baseline peritoneal kt/V urea values and the scores of the SF-36 components
---------------------------------------------------------------------------------------------------

More components of the SF-36 were influenced by peritoneal Kt/V values when the cutoff peritoneal Kt/V value was set at 1.2. General health, physical functioning, role limitation due to physical problems, and bodily pain scores had significantly improved when the peritoneal Kt/V value was above 1.2. In contrast, the scores for only the general health component improved when the peritoneal Kt/V value was below 1.2 (Table [1](#T1){ref-type="table"}).

Stratification of the patients on the basis of peritoneal kt/V urea and nPCR values
-----------------------------------------------------------------------------------

The patients were stratified into 2 groups on the basis of baseline Kt/V urea values above or below 1.2. The peritoneal Kt/V urea, total Kt/V urea, and weekly peritoneal Ccr values (Table [2](#T2){ref-type="table"}) were significantly different between both groups. When the patients were stratified according to an nPCR value above or below 1.2, those with nPCR values of ≥1.2 had higher total Kt/V urea and WCcr values than those with nPCR values of \<1.2 (Table [3](#T3){ref-type="table"}). The baseline scores for the SF-36 components did not differ between the groups stratified on the basis of cutoff values of 1.2 of Kt/V urea or nPCR values (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"})..

###### 

Baseline patient characteristics and SF-36 domains stratified by peritoneal Kt/V urea levels

                                        **Peritoneal Kt/V urea**                         
  ------------------------------------- -------------------------- --------------------- ----------
  Age (years)                           54.3 (19.9 - 68.1)         48.8 (17.6 - 80.1)    1
  Gender, Male (n)                      5                          33                    0.780\*
  DM, n (%)                             2 (18.2)                   20 (30.3)             0.392^a^
  BMI                                   20.1(14.4 -- 28.2)         20.5(16.4 -- 35.2)    0.760
  PD modality, CAPD/APD (n)             8/3                        34/32                 0.247\*
  Hb (g/dL)                             8.9 (3 - 13)               8.9 (6 - 12)          0.708
  Albumin (g/dL)                        3.6 (2.3 - 4.2)            3.6 (2.4 - 4.9)       0.86
  GPT (U/L)                             12 (4 - 41)                15 (3 - 458)          0.676
  Cr (mg/dL)                            12.4 (5.1 - 21.7)          12 (3.9 - 20.3)       1
  hs-CRP (mg/L)                         3.79 (0.2 - 40.1)          4.8 (0.2 - 199)       0.067
  Peritoneal Kt/V urea                  1.01 (0.7 - 1.2)           1.44 (1.2 - 2.3)      \<0.001
  Residual renal Kt/V urea              0.79 (0.2 - 4.1)           0.54 (0 - 2.1)        0.111
  Total Kt/V urea                       1.78 (1.1 - 4.8)           2.11 (1.2 - 3.3)      0.003
  Peritoneal WCcr L/week/1.73m^2^       31.5 (10.9 - 40.2)         37.1 (20.5 - 55.2)    \<0.001
  Residual renal WCcr L/week/1.73m^2^   38.6 (8.8 - 262.4)         29.8 (0 - 204.8)      0.103
  Total WCcr L/week/1.73m^2^            68.2 (44.9 - 348.4)        72.7 (31.4 - 226.7)   0.58
  nPCR                                  0.96 (0.5 - 1.5)           1.07 (0.5 - 1.6)      0.067
  Physical functioning                  76.7 (43.3 - 100)          76.7 (33.3 - 100)     0.727
  Role limitation - physical            65.4 (46.2 - 100)          61.5 (38.5 - 100)     0.931
  Bodily pain                           63.6 (27.3 - 100)          72.7 (27.3 - 100)     0.172
  General health                        35 (30 - 90)               40 (20 - 100)         0.148
  Vitality                              31.5 (11.1 - 46.3)         35.2 (7.4 - 53.7)     0.676
  Social functioning                    50 (20 - 100)              60 (20 - 100)         0.537
  Role limitation - emotional           63.6 (54.5 - 100)          72.7 (36.4 - 100)     0.382
  Mental health                         27.5 (20 - 45)             30 (5 - 50)           0.811

\* chi-square test, ^a^ likelihood ratio test.

###### 

Baseline patient characteristics and SF-36 domains stratified by nPCR levels

                                        **nPCR**                                    
  ------------------------------------- --------------------- --------------------- -----------
  Age (years)                           50.7 (17.6 - 80.1)    47.5 (19.9 - 68.1)    0.665
  Gender, Male (n)                      5                     33                    0.780\*
  DM, n (%)                             2 (18.2)              20 (30.3)             0.392^a^
  BMI                                   24.4 (16.4 -- 35.2)   20.6 (14.4 -- 25.8)   \<0.001
  PD modality, CAPD/APD (n)             26/29                 16/6                  \<0.01 \*
  Hb (g/dL)                             9 (3 - 13)            8.8 (6 - 11)          0.388
  Albumin (g/dL)                        3.6 (2.4 - 69)        3.5 (2.3 - 4.7)       0.663
  GPT (U/L)                             15 (3 - 458)          13.5 (7 - 39)         0.885
  Cr (mg/dL)                            11.5 (5.4 - 21.7)     12.6 (3.9 - 20.1)     0.564
  hs-CRP (mg/L)                         3.33 (0.2 - 199)      7.86 (0.5 - 65.2)     0.299
  Peritoneal Kt/V urea                  1.36 (0.7 - 2.3)      1.43 (0.7 - 2.2)      0.051
  Residual renal Kt/V urea              0.54 (0 - 1.44)       0.91 (0 - 4.1)        0.009
  Total Kt/V urea                       1.92 (1.1 - 3.0)      2.34 (1.8 - 4.8)      \<0.001
  Peritoneal WCcr L/week/1.73m^2^       35.3 (20.9 - 55.2)    36 (10.9 - 52.1)      0.973
  Residual renal WCcr L/week/1.73m^2^   29 (0 - 204.8)        39.2 (0 - 262.4)      0.167
  Total WCcr L/week/1.73m^2^            68.8 (31.4 - 226.7)   84.4 (45.6 - 348.4)   0.007
  nPCR                                  0.96 (0.5 - 1.2)      1.35 (1.2 - 1.6)      \<0.001
  Physical functioning                  76.7 (33.3 - 100)     78.3 (36.7 - 100)     0.612
  Role limitation - physical            61.5 (38.5 - 100)     65.4 (46.2 - 100)     0.769
  Bodily pain                           72.7 (27.3 - 100)     72.7 (27.3 - 100)     0.659
  General health                        40 (20 - 100)         35 (20 - 90)          0.416
  Vitality                              35.2 (7.4 - 51.9)     34.3 (11.1 - 44.4)    1
  Social functioning                    60 (20 - 100)         60 (20 - 80)          0.257
  Role limitation - emotional           68.2 (36.4 - 100)     68.2 (45.5 - 100)     1
  Mental health                         30 (10 - 50)          30 (5 - 45)           0.938

\* chi-square test, ^a^ likelihood ratio test

The effects of baseline peritoneal kt/V urea, renal WCcr, and nPCR values on the scores of the SF-36 components after 6 months of PD
------------------------------------------------------------------------------------------------------------------------------------

The patients who had baseline peritoneal Kt/V urea values of \<1.2 showed an improvement in physical functioning and role limitations due to physical problems after 6 months of PD therapy. Patients who had baseline peritoneal Kt/V urea of ≥1.2 showed improvement in general health, physical functioning, role limitation due to physical problems, and bodily pain (Table [4](#T4){ref-type="table"}). Residual renal function of either \<40 L·week^-1^·1.73 m^-2^ or ≥40 L·week^-1^·1.73 m^-2^ did not have an impact on SF-36 scores after 6 months of PD therapy. Deterioration was observed in all the components of the SF-36 after 6 months of PD therapy in patients with baseline nPCR values of \<1.2 (Table [4](#T4){ref-type="table"}).

###### 

Multivariate analysis using the general linear model to assess the difference of influence on the SF-36 between one month and six months following peritoneal dialysis therapy

                        **Physical functioning**   **Role limitation --physical**   **Bodily pain**                  **General health**                                                                                             
  --------------------- -------------------------- -------------------------------- -------------------------------- -------------------- ---------------- --------- --------- ---------------- --------- --------- --------------- ---------
  Age                   -0.309                     (-0.67-0.05)                     0.09                             -0.357               (-0.75-0.03)     0.07      -0.24     (-0.66-0.18)     0.262     -0.266    (-0.79-0.26)    0.32
  Peritoneal Kt/V                                                                                                                                                                                                                    
  \<1.2                 26.971                     (3.81-50.14)                     0.023                            34.326               (9.21-59.44)     0.008     25.518    (-1.88-52.91)    0.067     30.703    (-3.53-64.94)   0.078
  ≧1.2                  21.166                     (1.64-40.70)                     0.034                            26.026               (4.85-47.20)     0.017     23.245    (-0.15-46.34)    0.049     33.373    (4.51-62.24)    0.024
  Residual renal WCcr                                                                                                                                                                                                                
  \<40                  2.824                      (-7.24-12.89)                    0.578                            -4.666               (-15.58-6.25)    0.397     -3.383    (-15.29-8.52)    0.573     10.481    (-4.40-25.36)   0.164
  ≧40                   0                          \--                                                               0                    \--                        0         \--                        0         \--              
  nPCR                                                                                                                                                                                                                               
  \<1.2                 -5.645                     (-16.25-4.96)                    0.292                            -3.325               (-14.82-8.17)    0.566     -0.083    (-12.62-12.46)   0.99      -9.164    (-24.83-6.51)   0.247
  ≧1.2                  0                          \--                                                               0                    \--                        0         \--                        0         \--              
                        **Vitality**               **Social functioning**           **Role limitation- emotional**   **Mental health**                                                                                              
                        ***β***                    **(CI)**                         ***p***                          ***β***              **(CI)**         ***P***   ***β***   **(CI)**         ***P***   ***β***   **(CI)**        ***p***
  Age                   -0.089                     (-0.28-0.10)                     0.346                            0.107                (-0.42-0.63)     0.687     -0.154    (-0.55-0.24)     0.437     -0.142    (-0.37-0.08)    0.206
  Peritoneal Kt/V                                                                                                                                                                                                                    
  \<1.2                 11.974                     (-0.21-24.16)                    0.054                            6.724                (-27.39-40.83)   0.695     19.574    (-5.92-45.07)    0.13      11.234    (-3.18-25.65)   0.125
  ≧1.2                  9.276                      (-1.0-19.55)                     0.076                            2.663                (-26.09-31.42)   0.854     15.297    (-6.20-36.79)    0.16      8.402     (-3.75-20.55)   0.172
  Residual renal WCcr                                                                                                                                                                                                                
  \<40                  2.936                      (-2.36-8.23)                     0.273                            13.906               (-0.92-28.73)    0.066     -0.775    (-11.86-10.31)   0.889     0.949     (-5.32-7.21)    0.763
  ≧40                   0                          \--                                                               0                    \--                        0         \--                        0         \--              
  nPCR                                                                                                                                                                                                                               
  \<1.2                 -6.484                     (-12.06- -0.91)                  0.023                            -13.46               (-29.07-2.15)    0.09      -6.162    (-17.83-5.51)    0.296     -2.398    (-9.0-4.20)     0.471
  ≧1.2                  0                          \--                                                               0                    \--                        0         \--                        0         \--              

Multivariate analysis:

Discussion
==========

Small solute clearance measured by Kt/V urea is known to be one of the major determinants of dialysis adequacy. A growing body of evidence has suggested that a strong link exists between Kt/V urea values and mortality rates in dialysis populations \[[@B10]\]. Therefore, to reduce the risk of mortality and improve dialysis adequacy, the total (renal + peritoneal) Kt/V urea value should not be less than 1.7 for small solute removal, according to the guidelines of the Kidney Disease Outcomes Quality Initiative (KDOQI) and the International Society for Peritoneal Dialysis (ISPD) \[[@B11],[@B12]\]. To reach this target, however, patients might experience adverse effects, including hernias (from the increased intra-abdominal pressure due to large volumes of dialysis solution), weight gain, and other metabolic consequences due to increased exposure to glucose. Furthermore, the increased amount of time needed to perform the exchanges is less acceptable to patients. These factors might not only adversely affect the willingness of the patients to continue PD therapy but also affect the QoL in incident PD patients. However, one study reported that a lower Kt/V urea target was associated with a similar survival rate \[[@B13]\], leading us to consider what the impact of a lower Kt/V urea target would be on QoL. In our study, we carefully stratified our patients on the basis of peritoneal Kt/V urea values into 2 groups. Peritoneal Kt/V urea is the major component of total weekly Kt/V urea and is the critical component targeted in dialysis regimens. We found that patients with a peritoneal Kt/V urea value of \>1.2 experienced significant improvement in the QoL, especially in the domains of general health, physical function, and role limitation due to physical problems, at 6 months after the initiation of PD. Our results suggest that PD on its own is highly beneficial in improving the QoL in patients whose peritoneal Kt/V urea value is above 1.2. This result implies that some domains of the QoL could be improved after 6 months of PD therapy with a lower peritoneal Kt/V urea target. However, the influence of a lower peritoneal Kt/V urea value on long-term QoL and patient survival needs to be further investigated. Our study also suggests that it might not be necessary to pursue a higher adequacy target at the expense of QoL in the early phase of PD initiation. By not pursuing a higher adequacy target, the early discontinuation of incident PD patients observed occasionally can be avoided.

The nPCR value, also called protein equivalent of nitrogen appearance (PNA), can be used to assess dietary protein intake in patients who are in a steady state. It has also been adopted as a reference value to adjust dialysis prescription. When poor nutrition (e.g., nPCR \< 0.8 g·kg^-1^·day^-1^) or inadequate dialysis (e.g., Kt/V urea \< 1.2) is apparent, the dialysis prescription has to be adjusted to meet the clinical situation. Moreover, to ascertain whether a significant change has occurred may require several months of nPCR and Kt/V urea level monitoring. A previous study has demonstrated that mortality rates increased in dialysis patients with nPCR values of less than 0.8 g·kg^-1^·day^-1^ or greater than 1.4 g·kg^-1^·day^-1^\[[@B14]\]. Among patients with nPCR levels between 0.8 g·kg^-1^·day^-1^ and 1.2 g·kg^-1^·day^-1^, an increase or decrease in protein intake during the first 6 months was associated with an increase or decrease in the survival rate over the subsequent 18 months, respectively. Thus, reduced survival is associated with an initially low nPCR and decreased protein intake over time. In the present study, patients with baseline nPCR values of \>1.2 g·kg^-1^·day^-1^ had higher renal Kt/V urea values and higher weekly Ccr values than those with nPCR values of \<1.2 g·kg^-1^·day^-1^. Patients with nPCR values greater than 1.2 g·kg^-1^·day^-1^ showed improvement in SF-36 domain scores after 6 months of PD therapy. In contrast, patients with nPCR values of \<1.2 g·kg^-1^·day^-1^ showed a decrease in SF-36 domain scores after 6 months of PD therapy. The exact mechanism by which residual renal function improves the QoL in subjects with nPCR values of \>1.2 g·kg^-1^·day^-1^ needs to be further investigated. However, this finding implicates nutritional status as key factor in QoL improvement with PD initiation. Therefore, it is essential to devise a strategy to increase the nutritional status primarily in the early phase of PD commencement.

In the past few years, some investigators have focused on the reasons for the early discontinuation PD therapy by patients. The NECOSAD study demonstrated that the psychosocial effect of PD therapy was a one of the major reasons why patients discontinued therapy in the first 3 months \[[@B15]\]. Another study from a single PD center also showed that psychosocial effects were a major cause of early discontinuation of therapy in the first 6 months of PD therapy \[[@B16]\]. However, one study has shown that the measures of social relationships and physical health of PD patients did not significantly change during the early and late phases of treatment \[[@B17]\]. Furthermore, it has been found in one study that emotional defensiveness affects the physical and mental components of HRQoL in patients undergoing dialysis \[[@B18]\]. In that study, the incident PD patients needed an adjustment period to adapt to their uncertain psychological status; the complex, time-consuming PD exchange procedure affected their response to PD therapy. This finding suggests that psychological effects must not be ignored in the management of patients undergoing dialysis. Our study clearly showed that PD could improve the QoL, as measured by the SF-36 instrument, after 6 months of therapy. However, we found that a lower peritoneal Kt/V urea value further contributed to a remarkable improvement in the QoL. We assume that a more satisfactory PD prescription might reduce the psychosocial burden on incident PD patients, even though it would attain a lower adequacy index. This approach did not sacrifice the QoL in incident PD patients, as per our results.

Conclusion
==========

In summary, the QoL in incident PD patients can be improved with a low of Kt/V urea value in the PD prescription. Moreover, lower nPCR levels will offset the benefits of PD initiation on the QoL improvement. Additionally, a few aspects of the QoL domains in the SF-36 could be further improved in 6-month PD therapy in the cohort with low Kt/V urea levels. The results could guide medical staff in individualizing the medical plan for incident PD patients. We conclude that a stepwise PD program is essential for incident PD patients. This gradual approach to PD prescription need not be at the expense of QoL in incident PD patients.
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